We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Single Amino Acid Controls Signaling Molecule Activity

By LabMedica International staff writers
Posted on 09 Jan 2018
An advanced NMR (nuclear magnetic resonance) spectroscopy technique was used to follow the dynamic structural changes that occurred during binding of a drug to a cell membrane-spanning G protein-coupled receptor.

The 826 human G protein-coupled receptors (GPCRs), which are involved in signaling across cellular membranes, govern a wide range of vital physiological processes, making GPCRs prominent drug targets.

X-ray crystallography techniques have provided GPCR molecular architectures, but these methods lack the ability to detail additional structural dynamics that occur when the molecules are in motion. More...
To complete this picture, investigators at The Scripps Research Institute (La Jolla, CA, USA) used NMR spectroscopy to study the wild-type-like A2A adenosine receptor (A2AAR) in solution. A2AAR is a GPCR that regulates blood flow and inflammation and mediates the effects of caffeine. A2AAR is a validated target for treating Parkinson's disease and a relatively new target for targeting cancers.

To carry out this study the investigators assigned individual chemical markers to each of six tryptophan indole and eight glycine backbone NMR signals in A2AAR. These NMR probes provided insight into the role of a specific aspartic acid (Asp) moiety as an allosteric link between the drug binding site and the intracellular signaling surface.

Results published in the December 2, 2017, online edition of the journal Cell revealed that modifying or replacing this particular amino acid in the center of the receptor destroyed the receptor's ability to send signals into the cell. Furthermore, the NMR data showed that one of the tryptophan amino acids in A2AAR acted as a "toggle switch" by flipping up and down in concert with A2AAR's activity.

"This basic knowledge is potentially helpful for improving drug design," said senior author, the Nobel Prize winning Dr. Kurt Wüthrich, professor of structural biology at The Scripps Research Institute. "GPCRs do just about everything you can imagine, but for a long time, drug design was being done without knowing how GPCRs looked. With this finding, we can say "A-ha! It is this change in structure that kills the signaling activity." Maybe we can make a change in a drug to overcome this limit."

Related Links:
The Scripps Research Institute


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.